Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]

References

  1. ^ Seekamp A, van Griensven M, Dhondt E, Diefenbeck M, Demeyer I, Vundelinckx G, et al. (October 2004). "The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial". Critical Care Medicine. 32 (10): 2021–8. doi:10.1097/01.CCM.0000142396.59236.F3. PMID 15483410. S2CID 21172224.
source: https://en.wikipedia.org/wiki/Aselizumab